Change language dansk English suomi svenska

Generate Estimates Confirm Cancel Hide empty rows Show hidden rows DummyText

BIO-MEDICAL CONSULT HOLDING ApS Estimate generation in progress, please wait... 0%

Quicksearch from your own companies XBRLDenmark Analyst: XBRLDenmark

Loading... Loading... Loading... Loading...   Loading...

1000.0 Bankruptcy Risk  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Bankruptcy risk for industry   1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 0.6% 0.6%   Bankruptcy risk   1.2% 0.6% 0.5% 0.6% 1.0% 0.5% 8.1% 8.1%   Credit score (0-100)   83 98 99 97 88 99 30 30   Credit rating   A AA AA AA A AAA BB BB   Credit limit (kDKK)   327.3 1,485.2 1,599.3 1,602.5 973.9 1,613.2 0.0 0.0   How are these values calculated?   View the automatically generated explanation of bankruptcy risk 1000.0 Income statement (kDKK)  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales   0 0 0 0 0 0 0 0   Gross profit   18.1 -24.5 -29.7 -24.3 -18.4 -20.8 0.0 0.0   EBITDA   18.1 -24.5 -29.7 -24.3 -18.4 -20.8 0.0 0.0   EBIT   -52.5 -95.1 -100 -94.9 -66.9 -22.8 0.0 0.0   Pre-tax profit (PTP)   364.2 894.6 1,047.4 489.9 -1,800.0 1,362.4 0.0 0.0   Net earnings   551.3 644.8 937.4 398.3 -1,746.9 1,390.7 0.0 0.0   Pre-tax profit without non-rec. items   364 895 1,047 490 -1,800 1,362 0.0 0.0     See the entire income statement 1000.0 Balance sheet (kDKK)  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Tangible assets total   625 554 483 413 387 385 0.0 0.0   Shareholders equity total   14,612 15,257 16,194 16,592 14,845 16,236 13,332 13,332   Interest-bearing liabilities   1,844 2,100 2,453 2,372 2,809 2,956 0.0 0.0   Balance sheet total (assets)   17,988 17,520 18,790 19,075 17,931 19,335 13,332 13,332   Net Debt   -13,440 -12,449 -12,920 -13,231 -11,321 -12,403 -13,332 -13,332     See the entire balance sheet 1000.0 Volume  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales   0 0 0 0 0 0 0 0   Net sales growth   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Gross profit   18.1 -24.5 -29.7 -24.3 -18.4 -20.8 0.0 0.0   Gross profit growth   -99.4% 0.0% -21.5% 18.3% 24.1% -12.7% 0.0% 0.0%   Employees   0 0 0 0 0 0 0 0   Employee growth %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Employee expenses   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   17,988 17,520 18,790 19,075 17,931 19,335 13,332 13,332   Balance sheet change%   9.2% -2.6% 7.2% 1.5% -6.0% 7.8% -31.1% 0.0%   Added value   18.1 -24.5 -29.7 -24.3 3.8 -20.8 0.0 0.0   Added value %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Investments   -141 -141 -141 -141 -74 -4 -385 0   Net sales trend   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   EBIT trend   -1.0 -2.0 -3.0 -4.0 -5.0 -5.0 0.0 0.0   1000.0 Profitability  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A EBITDA %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT to gross profit (%)   -289.9% 388.7% 337.6% 390.9% 362.7% 109.9% 0.0% 0.0%   Net Earnings %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Profit before depreciation and extraordinary items %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Pre tax profit less extraordinaries %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   ROA %   11.4% 5.4% 6.0% 2.9% 2.2% 7.9% 0.0% 0.0%   ROI %   12.6% 5.6% 6.1% 2.9% 2.2% 8.0% 0.0% 0.0%   ROE %   3.8% 4.3% 6.0% 2.4% -11.1% 8.9% 0.0% 0.0%   1000.0 Solidity  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Equity ratio %   81.2% 87.1% 86.2% 87.0% 82.8% 84.0% 100.0% 100.0%   Relative indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Relative net indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net int. bear. debt to EBITDA, %   -74,191.8% 50,891.6% 43,470.9% 54,487.7% 61,399.1% 59,687.4% 0.0% 0.0%   Gearing %   12.6% 13.8% 15.1% 14.3% 18.9% 18.2% 0.0% 0.0%   Net interest   0 0 0 0 0 0 0 0   Financing costs %   131.2% 2.8% 2.2% 2.2% 85.4% 3.7% 0.0% 0.0%   1000.0 Liquidity  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Quick Ratio   4.8 6.8 6.2 6.6 4.8 5.2 0.0 0.0   Current Ratio   4.8 6.8 6.2 6.6 4.8 5.2 0.0 0.0   Cash and cash equivalent   15,283.9 14,548.3 15,372.7 15,603.2 14,130.4 15,359.4 0.0 0.0   1000.0 Capital use efficiency  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Trade debtors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Trade creditors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Current assets / Net sales %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net working capital   -1,869.6 -1,488.0 -1,870.6 -1,732.0 -1,422.8 -2,314.7 0.0 0.0   Net working capital %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   1000.0 Employee efficiency  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales / employee   0 0 0 0 0 0 0 0   Added value / employee   0 0 0 0 0 0 0 0   Employee expenses / employee   0 0 0 0 0 0 0 0   EBITDA / employee   0 0 0 0 0 0 0 0   EBIT / employee   0 0 0 0 0 0 0 0   Net earnings / employee   0 0 0 0 0 0 0 0